Dolby Laboratories, Inc.
DLB · NYSE
9/26/2025 | 6/27/2025 | 3/28/2025 | 12/27/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.21 | -0.78 | 0.62 | 1.69 |
| FCF Yield | 1.46% | 0.86% | 2.18% | 1.33% |
| EV / EBITDA | 103.67 | 90.11 | 48.30 | 62.35 |
| Quality | ||||
| ROIC | 1.06% | 1.42% | 3.09% | 2.47% |
| Gross Margin | 87.13% | 86.06% | 90.30% | 88.58% |
| Cash Conversion Ratio | 2.47 | 1.45 | 1.90 | 1.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.25% | 1.52% | 1.07% | 2.06% |
| Free Cash Flow Growth | 64.85% | -63.53% | 68.00% | -8.08% |
| Safety | ||||
| Net Debt / EBITDA | -10.98 | -9.22 | -4.91 | -5.10 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.30 | 1.36 | 1.04 | 1.28 |
| Cash Conversion Cycle | 178.72 | 174.23 | 176.06 | 186.00 |